Global Measles Vaccine

Measles Vaccine Comprehensive Study by Type (Mumps Measles Rubella Vaccine, Live (MMR-II), Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)), Application (Pediatric Vaccines, Adult Vaccines), End User (Hospitals, Clinics, Vaccination Centers) Players and Region - Global Market Outlook to 2030

Measles Vaccine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Measles Vaccine
Since, the air pollution is increasing with growing industrialization. Hence it will lead to propel the airborne diseases across the globe such as measles which is one of the severe and infectious diseases triggered by the airborne viruses. Initial symptoms of this disease are fever, cough, red eyes, and runny nose. After some days some people might observe tiny rashes on the body. According to the World Health Organization “In 2015, approximately 134200 people died globally due to measles.” MMR vaccines are the combination of measles, mumps, and rubella vaccine which is given to prevent measles in case of infants.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Measles Vaccine market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline Plc (United Kingdom), Sanofi-Pasteur (France), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Serum Institute of India Private Limited (India), China National Biotec Group Company Limited (China), Bavarian Nordic A/S (Denmark), Emergent Biosolutions (United States) and MedImmune, LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Johnson & Johnson (United States) and CSL Limited (Australia).

Segmentation Overview
AMA Research has segmented the market of Global Measles Vaccine market by Type (Mumps Measles Rubella Vaccine, Live (MMR-II) and Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)), Application (Pediatric Vaccines and Adult Vaccines) and Region.



On the basis of geography, the market of Measles Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the Measles Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Government Reimbursements for MMR Vaccine Development and Growing Success Rate of Vaccination Program with Minimized Side Effects

Market Growth Drivers:
Growing Instances of Airborne Diseases Due to Increasing Air Pollution and Rising Awareness about the MMR Vaccines

Challenges:
Minimizing the Side Effects of the Measles Vaccines and Maximum Cost for Single Dosage of Measles Vaccines

Restraints:
Vaccinations might cause Blooding Disorders in Children resulting in Rash like Reaction and Might cause High Temperature, Loss of Appetite and a General Feeling of being Unwell

Opportunities:
Increasing Availability of the MMR vaccines with respect to Increased Demand and Favorable Import and Export Facilities that Minimizes Distribution Overheads

Market Leaders and their expansionary development strategies
On 05th February 2019, GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers. Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.

Centre for Disease and Control Prevention recommends that people should get MMR vaccine to protect against measles, mumps, and rubella. Especially, Children should get two doses of MMR vaccine, starting with the first dose at 12 to 15 months of age, and the second dose at 4 through 6 years of age. Teens and adults should also be up to date on their MMR vaccination. Children may also get MMRV vaccine, which protects against measles, mumps, rubella, and varicella (chickenpox). This vaccine is only licensed for use in children who are 12 months through 12 years of age.

Key Target Audience
Measles Vaccine Manufacturers, Measles Vaccine Distributors, Traders, Suppliers, Pharmaceutical Industry Associations, Government Agencies, Healthcare Organizations, Research and Development Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Mumps Measles Rubella Vaccine, Live (MMR-II)
  • Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
By Application
  • Pediatric Vaccines
  • Adult Vaccines
By End User
  • Hospitals
  • Clinics
  • Vaccination Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Instances of Airborne Diseases Due to Increasing Air Pollution
      • 3.2.2. Rising Awareness about the MMR Vaccines
    • 3.3. Market Challenges
      • 3.3.1. Minimizing the Side Effects of the Measles Vaccines
      • 3.3.2. Maximum Cost for Single Dosage of Measles Vaccines
    • 3.4. Market Trends
      • 3.4.1. Increasing Government Reimbursements for MMR Vaccine Development
      • 3.4.2. Growing Success Rate of Vaccination Program with Minimized Side Effects
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Measles Vaccine, by Type, Application, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Measles Vaccine (Value)
      • 5.2.1. Global Measles Vaccine by: Type (Value)
        • 5.2.1.1. Mumps Measles Rubella Vaccine, Live (MMR-II)
        • 5.2.1.2. Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
      • 5.2.2. Global Measles Vaccine by: Application (Value)
        • 5.2.2.1. Pediatric Vaccines
        • 5.2.2.2. Adult Vaccines
      • 5.2.3. Global Measles Vaccine by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Vaccination Centers
      • 5.2.4. Global Measles Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Measles Vaccine (Volume)
      • 5.3.1. Global Measles Vaccine by: Type (Volume)
        • 5.3.1.1. Mumps Measles Rubella Vaccine, Live (MMR-II)
        • 5.3.1.2. Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
      • 5.3.2. Global Measles Vaccine by: Application (Volume)
        • 5.3.2.1. Pediatric Vaccines
        • 5.3.2.2. Adult Vaccines
      • 5.3.3. Global Measles Vaccine by: End User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Vaccination Centers
      • 5.3.4. Global Measles Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Measles Vaccine (Price)
      • 5.4.1. Global Measles Vaccine by: Type (Price)
  • 6. Measles Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi-Pasteur (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis International AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Serum Institute of India Private Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. China National Biotec Group Company Limited (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bavarian Nordic A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Emergent Biosolutions (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. MedImmune, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Measles Vaccine Sale, by Type, Application, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Measles Vaccine (Value)
      • 7.2.1. Global Measles Vaccine by: Type (Value)
        • 7.2.1.1. Mumps Measles Rubella Vaccine, Live (MMR-II)
        • 7.2.1.2. Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
      • 7.2.2. Global Measles Vaccine by: Application (Value)
        • 7.2.2.1. Pediatric Vaccines
        • 7.2.2.2. Adult Vaccines
      • 7.2.3. Global Measles Vaccine by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Vaccination Centers
      • 7.2.4. Global Measles Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Measles Vaccine (Volume)
      • 7.3.1. Global Measles Vaccine by: Type (Volume)
        • 7.3.1.1. Mumps Measles Rubella Vaccine, Live (MMR-II)
        • 7.3.1.2. Mumps Measles Rubella and Varicella Virus Vaccine (Proquad)
      • 7.3.2. Global Measles Vaccine by: Application (Volume)
        • 7.3.2.1. Pediatric Vaccines
        • 7.3.2.2. Adult Vaccines
      • 7.3.3. Global Measles Vaccine by: End User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Vaccination Centers
      • 7.3.4. Global Measles Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Measles Vaccine (Price)
      • 7.4.1. Global Measles Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Measles Vaccine: by Type(USD Million)
  • Table 2. Measles Vaccine Mumps Measles Rubella Vaccine, Live (MMR-II) , by Region USD Million (2018-2023)
  • Table 3. Measles Vaccine Mumps Measles Rubella and Varicella Virus Vaccine (Proquad) , by Region USD Million (2018-2023)
  • Table 4. Measles Vaccine: by Application(USD Million)
  • Table 5. Measles Vaccine Pediatric Vaccines , by Region USD Million (2018-2023)
  • Table 6. Measles Vaccine Adult Vaccines , by Region USD Million (2018-2023)
  • Table 7. Measles Vaccine: by End User(USD Million)
  • Table 8. Measles Vaccine Hospitals , by Region USD Million (2018-2023)
  • Table 9. Measles Vaccine Clinics , by Region USD Million (2018-2023)
  • Table 10. Measles Vaccine Vaccination Centers , by Region USD Million (2018-2023)
  • Table 11. South America Measles Vaccine, by Country USD Million (2018-2023)
  • Table 12. South America Measles Vaccine, by Type USD Million (2018-2023)
  • Table 13. South America Measles Vaccine, by Application USD Million (2018-2023)
  • Table 14. South America Measles Vaccine, by End User USD Million (2018-2023)
  • Table 15. Brazil Measles Vaccine, by Type USD Million (2018-2023)
  • Table 16. Brazil Measles Vaccine, by Application USD Million (2018-2023)
  • Table 17. Brazil Measles Vaccine, by End User USD Million (2018-2023)
  • Table 18. Argentina Measles Vaccine, by Type USD Million (2018-2023)
  • Table 19. Argentina Measles Vaccine, by Application USD Million (2018-2023)
  • Table 20. Argentina Measles Vaccine, by End User USD Million (2018-2023)
  • Table 21. Rest of South America Measles Vaccine, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Measles Vaccine, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Measles Vaccine, by End User USD Million (2018-2023)
  • Table 24. Asia Pacific Measles Vaccine, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Measles Vaccine, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Measles Vaccine, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Measles Vaccine, by End User USD Million (2018-2023)
  • Table 28. China Measles Vaccine, by Type USD Million (2018-2023)
  • Table 29. China Measles Vaccine, by Application USD Million (2018-2023)
  • Table 30. China Measles Vaccine, by End User USD Million (2018-2023)
  • Table 31. Japan Measles Vaccine, by Type USD Million (2018-2023)
  • Table 32. Japan Measles Vaccine, by Application USD Million (2018-2023)
  • Table 33. Japan Measles Vaccine, by End User USD Million (2018-2023)
  • Table 34. India Measles Vaccine, by Type USD Million (2018-2023)
  • Table 35. India Measles Vaccine, by Application USD Million (2018-2023)
  • Table 36. India Measles Vaccine, by End User USD Million (2018-2023)
  • Table 37. South Korea Measles Vaccine, by Type USD Million (2018-2023)
  • Table 38. South Korea Measles Vaccine, by Application USD Million (2018-2023)
  • Table 39. South Korea Measles Vaccine, by End User USD Million (2018-2023)
  • Table 40. Taiwan Measles Vaccine, by Type USD Million (2018-2023)
  • Table 41. Taiwan Measles Vaccine, by Application USD Million (2018-2023)
  • Table 42. Taiwan Measles Vaccine, by End User USD Million (2018-2023)
  • Table 43. Australia Measles Vaccine, by Type USD Million (2018-2023)
  • Table 44. Australia Measles Vaccine, by Application USD Million (2018-2023)
  • Table 45. Australia Measles Vaccine, by End User USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Measles Vaccine, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Measles Vaccine, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Measles Vaccine, by End User USD Million (2018-2023)
  • Table 49. Europe Measles Vaccine, by Country USD Million (2018-2023)
  • Table 50. Europe Measles Vaccine, by Type USD Million (2018-2023)
  • Table 51. Europe Measles Vaccine, by Application USD Million (2018-2023)
  • Table 52. Europe Measles Vaccine, by End User USD Million (2018-2023)
  • Table 53. Germany Measles Vaccine, by Type USD Million (2018-2023)
  • Table 54. Germany Measles Vaccine, by Application USD Million (2018-2023)
  • Table 55. Germany Measles Vaccine, by End User USD Million (2018-2023)
  • Table 56. France Measles Vaccine, by Type USD Million (2018-2023)
  • Table 57. France Measles Vaccine, by Application USD Million (2018-2023)
  • Table 58. France Measles Vaccine, by End User USD Million (2018-2023)
  • Table 59. Italy Measles Vaccine, by Type USD Million (2018-2023)
  • Table 60. Italy Measles Vaccine, by Application USD Million (2018-2023)
  • Table 61. Italy Measles Vaccine, by End User USD Million (2018-2023)
  • Table 62. United Kingdom Measles Vaccine, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Measles Vaccine, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Measles Vaccine, by End User USD Million (2018-2023)
  • Table 65. Netherlands Measles Vaccine, by Type USD Million (2018-2023)
  • Table 66. Netherlands Measles Vaccine, by Application USD Million (2018-2023)
  • Table 67. Netherlands Measles Vaccine, by End User USD Million (2018-2023)
  • Table 68. Rest of Europe Measles Vaccine, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Measles Vaccine, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Measles Vaccine, by End User USD Million (2018-2023)
  • Table 71. MEA Measles Vaccine, by Country USD Million (2018-2023)
  • Table 72. MEA Measles Vaccine, by Type USD Million (2018-2023)
  • Table 73. MEA Measles Vaccine, by Application USD Million (2018-2023)
  • Table 74. MEA Measles Vaccine, by End User USD Million (2018-2023)
  • Table 75. Middle East Measles Vaccine, by Type USD Million (2018-2023)
  • Table 76. Middle East Measles Vaccine, by Application USD Million (2018-2023)
  • Table 77. Middle East Measles Vaccine, by End User USD Million (2018-2023)
  • Table 78. Africa Measles Vaccine, by Type USD Million (2018-2023)
  • Table 79. Africa Measles Vaccine, by Application USD Million (2018-2023)
  • Table 80. Africa Measles Vaccine, by End User USD Million (2018-2023)
  • Table 81. North America Measles Vaccine, by Country USD Million (2018-2023)
  • Table 82. North America Measles Vaccine, by Type USD Million (2018-2023)
  • Table 83. North America Measles Vaccine, by Application USD Million (2018-2023)
  • Table 84. North America Measles Vaccine, by End User USD Million (2018-2023)
  • Table 85. United States Measles Vaccine, by Type USD Million (2018-2023)
  • Table 86. United States Measles Vaccine, by Application USD Million (2018-2023)
  • Table 87. United States Measles Vaccine, by End User USD Million (2018-2023)
  • Table 88. Canada Measles Vaccine, by Type USD Million (2018-2023)
  • Table 89. Canada Measles Vaccine, by Application USD Million (2018-2023)
  • Table 90. Canada Measles Vaccine, by End User USD Million (2018-2023)
  • Table 91. Mexico Measles Vaccine, by Type USD Million (2018-2023)
  • Table 92. Mexico Measles Vaccine, by Application USD Million (2018-2023)
  • Table 93. Mexico Measles Vaccine, by End User USD Million (2018-2023)
  • Table 94. Measles Vaccine Sales: by Type(K Liters)
  • Table 95. Measles Vaccine Sales Mumps Measles Rubella Vaccine, Live (MMR-II) , by Region K Liters (2018-2023)
  • Table 96. Measles Vaccine Sales Mumps Measles Rubella and Varicella Virus Vaccine (Proquad) , by Region K Liters (2018-2023)
  • Table 97. Measles Vaccine Sales: by Application(K Liters)
  • Table 98. Measles Vaccine Sales Pediatric Vaccines , by Region K Liters (2018-2023)
  • Table 99. Measles Vaccine Sales Adult Vaccines , by Region K Liters (2018-2023)
  • Table 100. Measles Vaccine Sales: by End User(K Liters)
  • Table 101. Measles Vaccine Sales Hospitals , by Region K Liters (2018-2023)
  • Table 102. Measles Vaccine Sales Clinics , by Region K Liters (2018-2023)
  • Table 103. Measles Vaccine Sales Vaccination Centers , by Region K Liters (2018-2023)
  • Table 104. South America Measles Vaccine Sales, by Country K Liters (2018-2023)
  • Table 105. South America Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 106. South America Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 107. South America Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 108. Brazil Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 109. Brazil Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 110. Brazil Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 111. Argentina Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 112. Argentina Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 113. Argentina Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 114. Rest of South America Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 115. Rest of South America Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 116. Rest of South America Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 117. Asia Pacific Measles Vaccine Sales, by Country K Liters (2018-2023)
  • Table 118. Asia Pacific Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 119. Asia Pacific Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 120. Asia Pacific Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 121. China Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 122. China Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 123. China Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 124. Japan Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 125. Japan Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 126. Japan Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 127. India Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 128. India Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 129. India Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 130. South Korea Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 131. South Korea Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 132. South Korea Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 133. Taiwan Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 134. Taiwan Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 135. Taiwan Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 136. Australia Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 137. Australia Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 138. Australia Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 139. Rest of Asia-Pacific Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 140. Rest of Asia-Pacific Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 141. Rest of Asia-Pacific Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 142. Europe Measles Vaccine Sales, by Country K Liters (2018-2023)
  • Table 143. Europe Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 144. Europe Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 145. Europe Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 146. Germany Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 147. Germany Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 148. Germany Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 149. France Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 150. France Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 151. France Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 152. Italy Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 153. Italy Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 154. Italy Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 155. United Kingdom Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 156. United Kingdom Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 157. United Kingdom Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 158. Netherlands Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 159. Netherlands Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 160. Netherlands Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 161. Rest of Europe Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 162. Rest of Europe Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 163. Rest of Europe Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 164. MEA Measles Vaccine Sales, by Country K Liters (2018-2023)
  • Table 165. MEA Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 166. MEA Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 167. MEA Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 168. Middle East Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 169. Middle East Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 170. Middle East Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 171. Africa Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 172. Africa Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 173. Africa Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 174. North America Measles Vaccine Sales, by Country K Liters (2018-2023)
  • Table 175. North America Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 176. North America Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 177. North America Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 178. United States Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 179. United States Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 180. United States Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 181. Canada Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 182. Canada Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 183. Canada Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 184. Mexico Measles Vaccine Sales, by Type K Liters (2018-2023)
  • Table 185. Mexico Measles Vaccine Sales, by Application K Liters (2018-2023)
  • Table 186. Mexico Measles Vaccine Sales, by End User K Liters (2018-2023)
  • Table 187. Measles Vaccine: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Measles Vaccine: by Type(USD Million)
  • Table 199. Measles Vaccine Mumps Measles Rubella Vaccine, Live (MMR-II) , by Region USD Million (2025-2030)
  • Table 200. Measles Vaccine Mumps Measles Rubella and Varicella Virus Vaccine (Proquad) , by Region USD Million (2025-2030)
  • Table 201. Measles Vaccine: by Application(USD Million)
  • Table 202. Measles Vaccine Pediatric Vaccines , by Region USD Million (2025-2030)
  • Table 203. Measles Vaccine Adult Vaccines , by Region USD Million (2025-2030)
  • Table 204. Measles Vaccine: by End User(USD Million)
  • Table 205. Measles Vaccine Hospitals , by Region USD Million (2025-2030)
  • Table 206. Measles Vaccine Clinics , by Region USD Million (2025-2030)
  • Table 207. Measles Vaccine Vaccination Centers , by Region USD Million (2025-2030)
  • Table 208. South America Measles Vaccine, by Country USD Million (2025-2030)
  • Table 209. South America Measles Vaccine, by Type USD Million (2025-2030)
  • Table 210. South America Measles Vaccine, by Application USD Million (2025-2030)
  • Table 211. South America Measles Vaccine, by End User USD Million (2025-2030)
  • Table 212. Brazil Measles Vaccine, by Type USD Million (2025-2030)
  • Table 213. Brazil Measles Vaccine, by Application USD Million (2025-2030)
  • Table 214. Brazil Measles Vaccine, by End User USD Million (2025-2030)
  • Table 215. Argentina Measles Vaccine, by Type USD Million (2025-2030)
  • Table 216. Argentina Measles Vaccine, by Application USD Million (2025-2030)
  • Table 217. Argentina Measles Vaccine, by End User USD Million (2025-2030)
  • Table 218. Rest of South America Measles Vaccine, by Type USD Million (2025-2030)
  • Table 219. Rest of South America Measles Vaccine, by Application USD Million (2025-2030)
  • Table 220. Rest of South America Measles Vaccine, by End User USD Million (2025-2030)
  • Table 221. Asia Pacific Measles Vaccine, by Country USD Million (2025-2030)
  • Table 222. Asia Pacific Measles Vaccine, by Type USD Million (2025-2030)
  • Table 223. Asia Pacific Measles Vaccine, by Application USD Million (2025-2030)
  • Table 224. Asia Pacific Measles Vaccine, by End User USD Million (2025-2030)
  • Table 225. China Measles Vaccine, by Type USD Million (2025-2030)
  • Table 226. China Measles Vaccine, by Application USD Million (2025-2030)
  • Table 227. China Measles Vaccine, by End User USD Million (2025-2030)
  • Table 228. Japan Measles Vaccine, by Type USD Million (2025-2030)
  • Table 229. Japan Measles Vaccine, by Application USD Million (2025-2030)
  • Table 230. Japan Measles Vaccine, by End User USD Million (2025-2030)
  • Table 231. India Measles Vaccine, by Type USD Million (2025-2030)
  • Table 232. India Measles Vaccine, by Application USD Million (2025-2030)
  • Table 233. India Measles Vaccine, by End User USD Million (2025-2030)
  • Table 234. South Korea Measles Vaccine, by Type USD Million (2025-2030)
  • Table 235. South Korea Measles Vaccine, by Application USD Million (2025-2030)
  • Table 236. South Korea Measles Vaccine, by End User USD Million (2025-2030)
  • Table 237. Taiwan Measles Vaccine, by Type USD Million (2025-2030)
  • Table 238. Taiwan Measles Vaccine, by Application USD Million (2025-2030)
  • Table 239. Taiwan Measles Vaccine, by End User USD Million (2025-2030)
  • Table 240. Australia Measles Vaccine, by Type USD Million (2025-2030)
  • Table 241. Australia Measles Vaccine, by Application USD Million (2025-2030)
  • Table 242. Australia Measles Vaccine, by End User USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Measles Vaccine, by Type USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Measles Vaccine, by Application USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Measles Vaccine, by End User USD Million (2025-2030)
  • Table 246. Europe Measles Vaccine, by Country USD Million (2025-2030)
  • Table 247. Europe Measles Vaccine, by Type USD Million (2025-2030)
  • Table 248. Europe Measles Vaccine, by Application USD Million (2025-2030)
  • Table 249. Europe Measles Vaccine, by End User USD Million (2025-2030)
  • Table 250. Germany Measles Vaccine, by Type USD Million (2025-2030)
  • Table 251. Germany Measles Vaccine, by Application USD Million (2025-2030)
  • Table 252. Germany Measles Vaccine, by End User USD Million (2025-2030)
  • Table 253. France Measles Vaccine, by Type USD Million (2025-2030)
  • Table 254. France Measles Vaccine, by Application USD Million (2025-2030)
  • Table 255. France Measles Vaccine, by End User USD Million (2025-2030)
  • Table 256. Italy Measles Vaccine, by Type USD Million (2025-2030)
  • Table 257. Italy Measles Vaccine, by Application USD Million (2025-2030)
  • Table 258. Italy Measles Vaccine, by End User USD Million (2025-2030)
  • Table 259. United Kingdom Measles Vaccine, by Type USD Million (2025-2030)
  • Table 260. United Kingdom Measles Vaccine, by Application USD Million (2025-2030)
  • Table 261. United Kingdom Measles Vaccine, by End User USD Million (2025-2030)
  • Table 262. Netherlands Measles Vaccine, by Type USD Million (2025-2030)
  • Table 263. Netherlands Measles Vaccine, by Application USD Million (2025-2030)
  • Table 264. Netherlands Measles Vaccine, by End User USD Million (2025-2030)
  • Table 265. Rest of Europe Measles Vaccine, by Type USD Million (2025-2030)
  • Table 266. Rest of Europe Measles Vaccine, by Application USD Million (2025-2030)
  • Table 267. Rest of Europe Measles Vaccine, by End User USD Million (2025-2030)
  • Table 268. MEA Measles Vaccine, by Country USD Million (2025-2030)
  • Table 269. MEA Measles Vaccine, by Type USD Million (2025-2030)
  • Table 270. MEA Measles Vaccine, by Application USD Million (2025-2030)
  • Table 271. MEA Measles Vaccine, by End User USD Million (2025-2030)
  • Table 272. Middle East Measles Vaccine, by Type USD Million (2025-2030)
  • Table 273. Middle East Measles Vaccine, by Application USD Million (2025-2030)
  • Table 274. Middle East Measles Vaccine, by End User USD Million (2025-2030)
  • Table 275. Africa Measles Vaccine, by Type USD Million (2025-2030)
  • Table 276. Africa Measles Vaccine, by Application USD Million (2025-2030)
  • Table 277. Africa Measles Vaccine, by End User USD Million (2025-2030)
  • Table 278. North America Measles Vaccine, by Country USD Million (2025-2030)
  • Table 279. North America Measles Vaccine, by Type USD Million (2025-2030)
  • Table 280. North America Measles Vaccine, by Application USD Million (2025-2030)
  • Table 281. North America Measles Vaccine, by End User USD Million (2025-2030)
  • Table 282. United States Measles Vaccine, by Type USD Million (2025-2030)
  • Table 283. United States Measles Vaccine, by Application USD Million (2025-2030)
  • Table 284. United States Measles Vaccine, by End User USD Million (2025-2030)
  • Table 285. Canada Measles Vaccine, by Type USD Million (2025-2030)
  • Table 286. Canada Measles Vaccine, by Application USD Million (2025-2030)
  • Table 287. Canada Measles Vaccine, by End User USD Million (2025-2030)
  • Table 288. Mexico Measles Vaccine, by Type USD Million (2025-2030)
  • Table 289. Mexico Measles Vaccine, by Application USD Million (2025-2030)
  • Table 290. Mexico Measles Vaccine, by End User USD Million (2025-2030)
  • Table 291. Measles Vaccine Sales: by Type(K Liters)
  • Table 292. Measles Vaccine Sales Mumps Measles Rubella Vaccine, Live (MMR-II) , by Region K Liters (2025-2030)
  • Table 293. Measles Vaccine Sales Mumps Measles Rubella and Varicella Virus Vaccine (Proquad) , by Region K Liters (2025-2030)
  • Table 294. Measles Vaccine Sales: by Application(K Liters)
  • Table 295. Measles Vaccine Sales Pediatric Vaccines , by Region K Liters (2025-2030)
  • Table 296. Measles Vaccine Sales Adult Vaccines , by Region K Liters (2025-2030)
  • Table 297. Measles Vaccine Sales: by End User(K Liters)
  • Table 298. Measles Vaccine Sales Hospitals , by Region K Liters (2025-2030)
  • Table 299. Measles Vaccine Sales Clinics , by Region K Liters (2025-2030)
  • Table 300. Measles Vaccine Sales Vaccination Centers , by Region K Liters (2025-2030)
  • Table 301. South America Measles Vaccine Sales, by Country K Liters (2025-2030)
  • Table 302. South America Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 303. South America Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 304. South America Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 305. Brazil Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 306. Brazil Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 307. Brazil Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 308. Argentina Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 309. Argentina Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 310. Argentina Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 311. Rest of South America Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 312. Rest of South America Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 313. Rest of South America Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 314. Asia Pacific Measles Vaccine Sales, by Country K Liters (2025-2030)
  • Table 315. Asia Pacific Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 316. Asia Pacific Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 317. Asia Pacific Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 318. China Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 319. China Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 320. China Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 321. Japan Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 322. Japan Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 323. Japan Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 324. India Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 325. India Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 326. India Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 327. South Korea Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 328. South Korea Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 329. South Korea Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 330. Taiwan Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 331. Taiwan Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 332. Taiwan Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 333. Australia Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 334. Australia Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 335. Australia Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 336. Rest of Asia-Pacific Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 337. Rest of Asia-Pacific Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 338. Rest of Asia-Pacific Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 339. Europe Measles Vaccine Sales, by Country K Liters (2025-2030)
  • Table 340. Europe Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 341. Europe Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 342. Europe Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 343. Germany Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 344. Germany Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 345. Germany Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 346. France Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 347. France Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 348. France Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 349. Italy Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 350. Italy Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 351. Italy Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 352. United Kingdom Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 353. United Kingdom Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 354. United Kingdom Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 355. Netherlands Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 356. Netherlands Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 357. Netherlands Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 358. Rest of Europe Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 359. Rest of Europe Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 360. Rest of Europe Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 361. MEA Measles Vaccine Sales, by Country K Liters (2025-2030)
  • Table 362. MEA Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 363. MEA Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 364. MEA Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 365. Middle East Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 366. Middle East Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 367. Middle East Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 368. Africa Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 369. Africa Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 370. Africa Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 371. North America Measles Vaccine Sales, by Country K Liters (2025-2030)
  • Table 372. North America Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 373. North America Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 374. North America Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 375. United States Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 376. United States Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 377. United States Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 378. Canada Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 379. Canada Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 380. Canada Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 381. Mexico Measles Vaccine Sales, by Type K Liters (2025-2030)
  • Table 382. Mexico Measles Vaccine Sales, by Application K Liters (2025-2030)
  • Table 383. Mexico Measles Vaccine Sales, by End User K Liters (2025-2030)
  • Table 384. Measles Vaccine: by Type(USD/Units)
  • Table 385. Research Programs/Design for This Report
  • Table 386. Key Data Information from Secondary Sources
  • Table 387. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Measles Vaccine: by Type USD Million (2018-2023)
  • Figure 5. Global Measles Vaccine: by Application USD Million (2018-2023)
  • Figure 6. Global Measles Vaccine: by End User USD Million (2018-2023)
  • Figure 7. South America Measles Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Measles Vaccine Share (%), by Country
  • Figure 9. Europe Measles Vaccine Share (%), by Country
  • Figure 10. MEA Measles Vaccine Share (%), by Country
  • Figure 11. North America Measles Vaccine Share (%), by Country
  • Figure 12. Global Measles Vaccine: by Type K Liters (2018-2023)
  • Figure 13. Global Measles Vaccine: by Application K Liters (2018-2023)
  • Figure 14. Global Measles Vaccine: by End User K Liters (2018-2023)
  • Figure 15. South America Measles Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Measles Vaccine Share (%), by Country
  • Figure 17. Europe Measles Vaccine Share (%), by Country
  • Figure 18. MEA Measles Vaccine Share (%), by Country
  • Figure 19. North America Measles Vaccine Share (%), by Country
  • Figure 20. Global Measles Vaccine: by Type USD/Units (2018-2023)
  • Figure 21. Global Measles Vaccine share by Players 2023 (%)
  • Figure 22. Global Measles Vaccine share by Players (Top 3) 2023(%)
  • Figure 23. Global Measles Vaccine share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Sanofi-Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi-Pasteur (France) Revenue: by Geography 2023
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Serum Institute of India Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 36. Serum Institute of India Private Limited (India) Revenue: by Geography 2023
  • Figure 37. China National Biotec Group Company Limited (China) Revenue, Net Income and Gross profit
  • Figure 38. China National Biotec Group Company Limited (China) Revenue: by Geography 2023
  • Figure 39. Bavarian Nordic A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 40. Bavarian Nordic A/S (Denmark) Revenue: by Geography 2023
  • Figure 41. Emergent Biosolutions (United States) Revenue, Net Income and Gross profit
  • Figure 42. Emergent Biosolutions (United States) Revenue: by Geography 2023
  • Figure 43. MedImmune, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 44. MedImmune, LLC (United States) Revenue: by Geography 2023
  • Figure 45. Global Measles Vaccine: by Type USD Million (2025-2030)
  • Figure 46. Global Measles Vaccine: by Application USD Million (2025-2030)
  • Figure 47. Global Measles Vaccine: by End User USD Million (2025-2030)
  • Figure 48. South America Measles Vaccine Share (%), by Country
  • Figure 49. Asia Pacific Measles Vaccine Share (%), by Country
  • Figure 50. Europe Measles Vaccine Share (%), by Country
  • Figure 51. MEA Measles Vaccine Share (%), by Country
  • Figure 52. North America Measles Vaccine Share (%), by Country
  • Figure 53. Global Measles Vaccine: by Type K Liters (2025-2030)
  • Figure 54. Global Measles Vaccine: by Application K Liters (2025-2030)
  • Figure 55. Global Measles Vaccine: by End User K Liters (2025-2030)
  • Figure 56. South America Measles Vaccine Share (%), by Country
  • Figure 57. Asia Pacific Measles Vaccine Share (%), by Country
  • Figure 58. Europe Measles Vaccine Share (%), by Country
  • Figure 59. MEA Measles Vaccine Share (%), by Country
  • Figure 60. North America Measles Vaccine Share (%), by Country
  • Figure 61. Global Measles Vaccine: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline Plc (United Kingdom)
  • Sanofi-Pasteur (France)
  • Merck & Co., Inc. (United States)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Serum Institute of India Private Limited (India)
  • China National Biotec Group Company Limited (China)
  • Bavarian Nordic A/S (Denmark)
  • Emergent Biosolutions (United States)
  • MedImmune, LLC (United States)
Additional players considered in the study are as follows:
Johnson & Johnson (United States) , CSL Limited (Australia)
Select User Access Type

Key Highlights of Report


Jun 2024 249 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Measles Vaccine Quantitative research analysis
Global Measles Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline Plc (United Kingdom), Sanofi-Pasteur (France), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Serum Institute of India Private Limited (India), China National Biotec Group Company Limited (China), Bavarian Nordic A/S (Denmark), Emergent Biosolutions (United States) and MedImmune, LLC (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Government Reimbursements for MMR Vaccine Development " is seen as one of major influencing trends for Measles Vaccine Market during projected period 2023-2030.
The Measles Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Measles Vaccine Report?

Have a Query? Click Here

Other Related Reports

Meningococcal Vaccines Comprehensive Study by Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, Others), Application (Pneumonia, Meningitis, Bacteremia, Others (Arthritis, Conj...
$ 3750
Asthma Treatment Drugs Comprehensive Study by Type (Long-term Control Medications, Quick-relief Medications (Rescue Medications), Medications for Allergy-induced Asthma), Application (Hospital Pharma...
$ 3750
Nevirapine Comprehensive Study by Type (100 mg, 200 mg, 400 mg), Application (Women (Pregnant, Non- pregnant), Men), Method (Antiretroviral Therapy, Hepatotoxicity) Players and Region - Global Market...
$ 3500
Medication Adherence Packaging Systems Comprehensive Study by Type (Unit-dose Packaging Systems, Multi-dose Packaging Systems), Packaging (Ampoules, Vials, Prefilled Syringes & Injectable, Blisters, ...
$ 3750
Osteoarthritis Pain Drugs Comprehensive Study by Type (Oral, Injection, External), Application (Medical Care, Personal Care), Therapies (Non- Pharmacological Therapy, Pharmacological Therapy, Surgica...
$ 3750
Docusate Sodium Comprehensive Study by Type (DSS 100%, DSS 85%, DSS 50%), Application (Exicipient, Active Pharmaceutical Ingredients, Constipation, Pesticide adjuvant, Micelle encapsulation), Route o...
$ 3650